Trial Profile
A phase 2 double-blind randomized study of oral enzastaurin HCl versus placebo concurrently with pemetrexed (Alimta) as second-line therapy in patients with advanced or metastatic non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 19 Jan 2010 Results presented in the Journal of Thoracic Oncology.
- 04 Aug 2009 Results presented at IASLC 2009.
- 01 Aug 2009 Tolerability and quality of life results have been reported at the 13th World Conference on Lung Cancer.